Unraveling Systemic Responses to NQO1-Activated IB-DNQand Rucaparib Single and Dual Agent Therapy in Triple-Negative Breast Cancers
A. M. Runnebohm, H. S. Wijeratne, S. A. Peck Justice, A. B. Wijeratne, G. Roy, J. J. Smith, N. Singh, P. Hergenrother, D. A. Boothman, E. A. Motea, A. L. Mosley
This study evaluates the effects of IB-DNQ and Rucaparib on TNBC cells, revealing synergistic effects and novel protein biophysical changes via thermal proteome profiling.
bioRxiv · May 15, 2024 · PreprintCancer Biology